Summary & Overview
CPT 81251: GBA Gene Variant Detection, Molecular Genetic Test
CPT code 81251 designates a molecular diagnostic laboratory procedure to detect specific genetic changes in the glucosidase, beta, acid (GBA) gene. Tests targeting GBA variants have clinical relevance for inherited metabolic disorders and certain neurodegenerative conditions, making the code important for genetic diagnostic workflows, care planning, and population health monitoring.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The summary presents payer coverage considerations, typical sites of service, and clinical context for GBA testing.
Readers will find a compact review of what CPT code 81251 represents, how it fits into molecular laboratory service lines, and the clinical situations in which GBA variant detection is used. The publication also provides national-level benchmarking elements where available, notes on common billing modifiers (listed separately), and context on how GBA testing informs diagnosis and management. Data not available in the input is clearly identified where applicable.
Billing Code Overview
CPT code 81251 reports a laboratory test that detects the presence of specific changes in the gene for glucosidase, beta, acid (GBA). This is a molecular genetic diagnostic test targeting variants in the GBA gene that are relevant to inherited metabolic and neurodegenerative conditions.
Service Type: Molecular genetic testing / Laboratory genetics service
Typical Site of Service: Clinical molecular laboratory or reference diagnostic laboratory
Clinical & Coding Specifications
Clinical Context
A patient presents for molecular testing to evaluate for pathogenic variants in the GBA (glucocerebrosidase) gene. Typical scenarios include a symptomatic adult or child with clinical features suggestive of Gaucher disease (hepatosplenomegaly, cytopenias, bone pain or crises, growth delay) or a patient with a family history of Gaucher disease or known GBA variant seeking carrier testing or cascade testing. Testing may also be ordered for patients with parkinsonism when GBA variant status is relevant to prognosis or research.
The clinical workflow begins with a genetics or specialty clinic visit (medical genetics, hematology, neurology, or metabolic clinic) where history, family history, and exam findings are documented and informed consent for genetic testing is obtained. A specimen (typically blood in EDTA or saliva per lab policy) is collected and sent to a molecular laboratory. The laboratory performs targeted sequencing, full gene sequencing, or a panel including GBA; CPT 81251 covers the technical laboratory analytic work to detect GBA gene changes. The laboratory issues a technical report and a separate interpretive/professional report when applicable. Results are returned to the ordering provider for clinical interpretation, counseling, and management decisions, including referral to genetics, hematology, or neurology as appropriate.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 |